{"entity":{"id":"sant-chawla","kind":"person","name":"Sant P. Chawla","aka":[],"tldr":"The Santa Monica medical oncologist whose sarcoma practice has run many of the field's early and late phase drug trials, including the aldoxorubicin programme.","summary":"Sant Chawla is Medical Director of the Sarcoma Oncology Center in Santa Monica, California, a sarcoma-focused practice that its site describes as offering access to clinical trials and novel investigational therapies alongside multimodal treatment planning. He is board certified in internal medicine and medical oncology. OnCo's record of the centre notes that he led the aldoxorubicin trials in soft tissue sarcoma and co-founded Gemini Therapeutics, the company formed to carry aldoxorubicin forward. His publications are listed on PubMed.","asOf":"2026-09-17","links":[{"label":"Sarcoma Oncology Center","url":"https://www.sarcomaoncology.com/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chawla+SP%5BAuthor%5D+sarcoma"}],"tags":["leadership","trialist"],"related":[],"cancers":["sarcoma","osteosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["aldoxorubicin"],"companies":["gemini-therapeutics"],"institutions":["sarcoma-oncology-center"],"pathways":[],"terms":[],"trials":["aldoxorubicin-phase-3-sts"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Director, Sarcoma Oncology Center","institutionId":"sarcoma-oncology-center","specialisms":["Sarcoma","Early phase trials","Medical oncology"],"profiles":[{"label":"Sarcoma Oncology Center","url":"https://www.sarcomaoncology.com/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chawla+SP%5BAuthor%5D+sarcoma"}],"papers":[{"title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","journal":"Lancet Oncology","year":2020,"url":"https://doi.org/10.1016/S1470-2045(19)30691-6","doi":"10.1016/S1470-2045(19)30691-6","note":"Europe PMC author record matched by affiliation"},{"title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","journal":"Lancet Oncology","year":2020,"url":"https://doi.org/10.1016/S1470-2045(20)30068-1","doi":"10.1016/S1470-2045(20)30068-1","note":"Europe PMC author record matched by affiliation"},{"title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial","journal":"Lancet Oncology","year":2017,"url":"https://doi.org/10.1016/S1470-2045(17)30381-9","doi":"10.1016/S1470-2045(17)30381-9","note":"Europe PMC author record matched by affiliation"}]},"route":"/people/sant-chawla/","neighbours":{"cancer":[{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"drug":[{"id":"aldoxorubicin","kind":"drug","name":"Aldoxorubicin","route":"/drugs/aldoxorubicin/"}],"company":[{"id":"gemini-therapeutics","kind":"company","name":"Gemini Therapeutics","route":"/companies/gemini-therapeutics/"}],"institution":[{"id":"sarcoma-oncology-center","kind":"institution","name":"Sarcoma Oncology Center","route":"/institutions/sarcoma-oncology-center/"}],"trial":[{"id":"aldoxorubicin-phase-3-sts","kind":"trial","name":"Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma","route":"/trials/aldoxorubicin-phase-3-sts/"}]}}